Trends in cancerReview
26 Nov 2024
Cancer treatment has entered the age of immunotherapy. Immune checkpoint inhibitor (ICI) therapy has shown robust therapeutic potential in clinical practice, with significant improvements in progression-free survival (PFS) and overall survival (OS). Recently, checkpoint blockade of the lymphocyte activation gene 3 (LAG3) inhibitory receptor (IR) in combination with programmed death protein 1 (PD1) inhibition has been FDA approved in patients with advanced melanoma. This has encouraged the clinical evaluation of new LAG3-directed biologics in combination with other checkpoint inhibitors. Several of these studies are evaluating bispecific antibodies that target exhausted T (T) cells expressing multiple IRs. This review discusses the current understanding of LAG3 in regulating antitumor immunity and the ongoing clinical testing of LAG3 inhibition in cancer.
Declaration of interests The authors declare competing financial interests. D.A.A.V. and C.J.W. have patents covering LAG3, with others pending, and are entitled to a share of net income generated from licensing of these patent rights for commercial development. D.A.A.V.: cofounder and stock holder – Novasenta, Potenza, Tizona, Trishula; stock holder – Werewolf; patents licensed and royalties – BMS, Novasenta; scientific advisory board member – Werewolf, F-Star, Apeximmune, T7/Imreg Bio; consultant – BMS, Regeneron, Ono Pharma, Peptone, Avidity Partners, Third Arc Bio, Secarna, Curio Bio; funding – BMS, Novasenta. The remaining authors declare no competing interests.
More resources:
Share: